Adverse outcomes and magnitude of benefit with glycoprotein IIb/IIa inhibit - Evidencio
Adverse outcomes and magnitude of benefit with glycoprotein IIb/IIa inhibitor therapy.
Identifies patients with unstable angina or non-ST elevation myocardial infarction at high risk for death and cardiac ischemic events and who experience the greatest benefit from the addition of a glycoprotein IIb/IIIa inhibitor to their treatment regimen.
Auteurs: Sabatine MS, Januzzi JL, Snapinn S, Théroux P, Jang IK
Versie: 1.16
  • Publiek
  • Klinische farmacologie
  • {{ modelType }}
  • Details
  • Valideer algoritme
  • Bewaar invoer
  • Laad invoer
Weergave
Eenheden

{{ section.title }}

{{ section.description }}

Bereken het resultaat

Vul meer parameters in om de berekening uit te voeren

Total risk score: points

{{ resultSubheader }}
{{ $t('download_result_availability') }}
{{ chart.title }}
Resultaat interval {{ additionalResult.min }} tot {{ additionalResult.max }}

Conditionele informatie

How this model should be used: 
This model can be used to identify patients at high risk for death and cardiac ischemic events and who experience the greatest benefit from the addition of a glycoprotein IIb/IIIa inhibitor to their treatment regimen.

Model performance: 
There was a progressive increase in the rate of the composite end point of death, myocardial infarction, or refractory ischemia at 7 days with an increasing number of risk factors. For patients treated with heparin alone, the composite end point event rate was 6.5% in the group with 0 or 1 predictor, 14.6% in the group with 2 predictors, 22.7% in the group with 3 predictors, and 37.1% in the group with 4 or 5 predictors (p <0.00001). When dividing patients into low- (0 or 1 point), medium- (2 or 3 points), and high-risk (4 or 5 points) groups, the addition of tirofiban to heparin therapy was associated with no significant benefit in the low-risk group, a 5.2% absolute reduction in the medium-risk group (p = 0.05), and a 16% absolute reduction in the high-risk group (p = 0.0055). 

Source:
Sabatine MS, Januzzi JL, Snapinn S, et al. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoproteinIIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol. 2001;88(5):488-92.

{{ file.classification }}
PRO
Notitie
Notities zijn alleen zichtbaar in de resultaat download en worden niet opgeslagen door Evidencio

Dit algoritme wordt verstrekt voor educatieve, opleidings- en informatieve doeleinden. Het mag niet worden gebruikt ter ondersteuning van medische besluitvorming, of om medische of diagnostische diensten te verlenen. Lees onze volledige disclaimer.

Onderliggende algoritmes Onderdeel van
Opmerkingen
Opmerking
Vul een opmerking in.
Opmerkingen zijn voor iedereen zichtbaar

Algoritme feedback

Nog geen feedback 1 Opmerking {{ model.comments.length }} Opmerkingen
Op {{ comment.created_at }} {{ comment.user.username }} een niet langer geregistreerde auteur schreef:
{{ comment.content }}
logo

Log a.u.b. in om de Evidencio print-functies te gebruiken

Om de Evidencio print-functies te kunnen gebruiken dient u ingelogt te zijn.
Indien u nog geen Evidencio Community Account heeft kunt u eenvoudig een persoonlijk account aanmaken op:

https://www.evidencio.com/registration

Print rapport - Voorbeelden {{ new Date().toLocaleString() }}

Evidencio Community Account voordelen

With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.

Disclaimer: Predictie algoritmes dienen enkel ter ondersteuning en naslag geraadpleegd te worden en zijn geen vervanging voor medische besluitvorming door professionals.
Algemene voorwaarden | Privacy Policy | Disclaimer | Contact | Cookies weigeren |
Evidencio v3.38 © 2015 - 2025 Evidencio. Alle rechten voorbehouden